Omar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omar

What is Omar? (Omeprazole)

Property Description
Active ingredient Omeprazole (often as Omeprazole magnesium)
Form Delayed-release capsule, Enteric-coated tablet, IV injection
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic, benzimidazole derivative

What Type of Medicine Is Omar (Omeprazole)?

Omar is a medicinal product containing the active ingredient Omeprazole, which belongs to the therapeutic group known as Proton Pump Inhibitors (PPIs). This pharmacological class is characterized by its highly specific and sustained ability to limit the production of acid within the stomach. Omeprazole is a synthetic compound, chemically classified as a substituted benzimidazole derivative. PPIs are clinically recognized for achieving profound acid suppression, differing structurally and functionally from older categories such as H2-receptor antagonists.

Composition and Physical Forms of Omar

The essential component of Omar is Omeprazole, typically used as its salt, Omeprazole magnesium, supplied as a single-ingredient drug. Because the substance is inherently acid-labile—meaning it is susceptible to degradation by stomach acid—specialized dosage forms are utilized. These commonly include the delayed-release capsule and the enteric-coated tablet, which are engineered to protect the active ingredient until it reaches the small intestine for absorption. This delayed-release feature is critical to the drug's intended efficacy. The product is also available as a powder for Intravenous (IV) injection, expanding the options for parenteral administration.

General Purpose and Action Principle

The fundamental purpose of Omar is to significantly reduce the overall amount of acid secreted by the stomach, providing a protective effect to the upper gastrointestinal lining. This general physiological benefit stems from the drug’s action as a highly effective gastric acid secretion inhibitor. Omeprazole functions by achieving irreversible inhibition of the Proton Pump (H^+K^+-ATPase enzyme system) in the stomach wall, the core mechanism of the drug's action. This inhibition ensures that the drug provides long-lasting control over acid formation, creating an environment necessary to mitigate the irritative effects of excessive acid.

Regulatory References

  1. WHO Essential Medicines List for Omeprazole

What side effects are possible with Omar?

Possible Side Effects and Safety Information

Omar (Omeprazole) is associated with a defined safety profile derived exclusively from official regulatory documents. Side effects are classified by frequency and System-Organ Class (SOC) based on data from post-marketing surveillance and clinical trials.

Documented Adverse Reactions

The most common adverse reactions officially listed in regulatory information include headache and various gastrointestinal disorders such as abdominal pain, constipation, diarrhea, flatulence, nausea, and vomiting. These are classified as Common (affecting ge 1/100 people).

Less common effects (Uncommon or Rare) involve other systems, including dizziness, insomnia, dermatitis/rash, and increased liver enzymes.

Frequency Classification Examples of Documented Effects
Common Headache, Abdominal pain, Nausea, Diarrhea, Flatulence
Uncommon Dizziness, Insomnia, Dermatitis, Increased liver enzymes
Rare Confusion, Depression, Hypersensitivity reactions (e.g., Angioedema)

Serious Adverse Reactions and Safety Constraints

The official labeling notes rare, but clinically significant, serious adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis (TEN), as well as Acute Interstitial Nephritis (TIN). Rare blood disorders like agranulocytosis and the potential for hepatic failure in patients with pre-existing liver disease are also documented.

Duration-Related Safety: Long-term use (typically ge 1 year) is associated with an increased risk of bone fractures of the hip, wrist, or spine, and the formation of benign Fundic Gland Polyps. Prolonged therapy (ge 3 years) may also lead to a deficiency of Vitamin B-12. Additionally, the medicine carries a documented risk of Hypomagnesaemia (low serum magnesium) and is associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD).

Overdose and Emergency Response

The official regulatory documentation for Omeprazole (Omar) emphasizes that experience with massive overdose is limited, but generally, reported presentations are mild, transient, and reversible. Manifestations documented following accidental or intentional overexposure include general symptoms such as headache, nausea, vomiting, abdominal pain, and diarrhea. Other listed signs include somnolence (drowsiness) and **blurred vision).

The drug’s official profile notes that more serious clinical effects have been reported, involving the central nervous system (e.g., confusion, tremor) and the cardiovascular system, including tachycardia (fast heartbeat). These documented manifestations underscore the requirement for urgent professional assessment.

Regulatory authorities mandate that if an overdose of Omar is known or suspected, immediate medical attention must be sought. It is required to contact a Poison Control Center or emergency medical services without delay. The established management strategy documented in official labels is strictly symptomatic and supportive treatment. This means care focuses only on alleviating the patient's specific clinical signs. No specific antidote is known for Omeprazole overdose, and the substance's high plasma protein binding means that standard procedures like dialysis are not expected to be an effective method of removal.

Therapeutic Uses of Omar

Quick Facts

  • Treatment Area: Conditions associated with excess stomach acid
  • Primary Uses: Gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome
  • Core Benefit: Supports the reduction of acid secretion in the stomach

Omar is an established treatment utilized for managing conditions that result from excessive acid production in the stomach. Its primary therapeutic domains include providing symptomatic relief in individuals with Gastroesophageal Reflux Disease (GERD) by helping to manage heartburn and acid regurgitation. This approach allows for the healing of irritation in the esophagus and stomach lining.

Additionally, the medication is applied in the management of ulcers in both the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). For ulcers linked to the bacterium Helicobacter pylori, Omar is administered as part of a combination regimen with antibiotics. Furthermore, it is a component of the treatment protocol for Zollinger-Ellison syndrome, a condition where the stomach produces an unusually high volume of acid, aiming to help control acid levels. Omeprazole, the active component in products designated as Omar, is utilized in the management of these acid-related disorders.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for the use of Omar, as documented in government regulatory sources such as the FDA and EMA. Understanding these constraints is essential for safe use.

Eligibility Scope

Scope Item Regulatory Statement
Populations for whom use is contraindicated: [No specific absolute contraindications found in current regulatory searches.]
Age-related eligibility rules: [Specific data for pediatric or geriatric use limitations is not currently documented in available government sources.]
Condition-specific eligibility rules: [Official restrictions related to specific organ impairments, such as hepatic or renal failure, are not currently specified.]
Pregnancy and lactation eligibility status: [Explicit regulatory status for use during pregnancy or breastfeeding is not currently stated.]

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines who must not use the medicine through formalized contraindications and identifies populations requiring special caution, such as those with certain comorbidities. This framework ensures that any known, label-documented risks associated with specific patient groups or life stages are explicitly addressed before use, adhering to a patient-safety standard defined by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omar (Omeprazole) has officially documented interaction patterns based primarily on two pharmacological effects: its role as a CYP2C19 enzyme inhibitor and its sustained effect of elevating gastric pH.


Official Use Restrictions

The most restrictive interactions are with certain antiretroviral agents. The co-administration of Omeprazole with medicines such as Atazanavir, Nelfinavir, and Rilpivirine is not recommended in regulatory labeling because Omeprazole significantly reduces the plasma concentrations of these agents, diminishing their therapeutic efficacy.

Pharmacokinetic and Absorption Interactions

Omeprazole's inhibition of the CYP2C19 enzyme affects the metabolism of other drugs, resulting in diminished anti-platelet activity when co-administered with Clopidogrel. Furthermore, Omeprazole can increase the systemic exposure of drugs like Diazepam, Phenytoin, Tacrolimus, and Cilostazol due to reduced clearance. The elevation of gastric pH reduces the absorption and effectiveness of medicines that require an acidic environment, including certain oral antifungal agents (e.g., Ketoconazole, Itraconazole) and specific iron salts. Conversely, Omeprazole concentrations may be reduced by co-administration with enzyme inducers like St John's Wort or Rifampin.


Procedural and Population Constraints

Official labeling mandates a timing separation rule: Omeprazole must be temporarily stopped at least 14 days before assessing Chromogranin A (CgA) levels for diagnostic purposes. Regulatory documents also note that the interaction potential may be heightened in individuals identified as CYP2C19 Poor Metabolizers, who exhibit greater systemic exposure to Omeprazole.

Mechanism of Action

How Omar Works

Targeted Inhibition of Calcineurin

Omar’s primary mechanism of action involves the inhibition of the enzyme calcineurin within T-lymphocytes. The drug binds to an intracellular receptor to form a complex that inhibits this enzyme's phosphatase activity, an early step in the cell activation pathway. This action modulates signaling pathways involved in T-cell activity, which results in altered T-cell function.

Blockade of Genetic Transcription

By inhibiting calcineurin, the drug prevents a necessary activation step for the NFAT transcription factor, thereby stopping it from entering the cell nucleus. This mechanism blocks the genetic instructions (transcription) required to produce specific messenger proteins like Interleukin-2. This sequence of events results in reduced T-cell proliferation and differentiation, which underlies the drug’s physiological effect on cell-mediated immunity.

Dosage and Administration Information

How to Use Omar

The usage of Omeprazole (Omar) is governed by specific established guidelines, primarily focusing on administration route, timing, frequency, and dosage ranges.

Dosing and Frequency

Omar is utilized for oral administration via delayed-release capsules or tablets, and also as an intravenous (IV) injection for instances where oral intake is not appropriate. The oral dose is typically taken before eating to ensure proper action. To preserve the enteric coating, the capsules or tablets must be swallowed whole and must not be chewed or crushed. For patients who cannot swallow the capsule, the contents may be mixed with a slightly acidic food, such as applesauce, and consumed immediately.

Dosing Parameters and Frequency

The most common usage pattern involves a once-daily (QD) frequency for both maintenance therapy and short-term courses for conditions like Erosive Esophagitis and symptomatic GERD. Dosage typically starts at 20 mg or 40 mg once daily, depending on the specific condition being addressed. For complex conditions that require high levels of acid suppression, such as Zollinger-Ellison syndrome, doses can range significantly; however, total daily doses exceeding 80 mg are generally administered in divided doses.

Course Duration and Specific Populations

Treatment courses are often short-term, such as four to eight weeks for active ulcer treatment. However, the medicine is also utilized as part of a long-term plan for maintaining the healing of the esophagus and managing chronic hypersecretory states. Dosing for pediatric patients is determined based on weight. A dose reduction is considered for patients with severe hepatic impairment, while no routine adjustment is generally required for those with renal impairment or older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Omar (Omeprazole)


Evidence for Gastroesophageal Reflux Disease (GERD) and Heartburn

Research has explored the medicine using controlled clinical trials and meta-analyses. These Randomized Controlled Trials (RCTs) often compare the medicine against a placebo (an inactive substance) or against other acid-reducing therapies. Studies were conducted during periods of increased symptom activity in adults with conditions characterized by fluctuating or episodic manifestations like heartburn and acid regurgitation.

The primary outcomes research examined were patient-reported outcomes describing perceived discomfort, such as the measurement of changes in symptom duration and the proportion of individuals who reported complete resolution of symptoms after specific short-term treatment intervals, such as two to four weeks. The results apply only to the populations studied. Also, the body of evidence focusing solely on the medicine's use for acute, temporary symptom flares outside of a continuous treatment plan is considered limited.


Evidence for Healing of Erosive Esophagitis and Ulcers

Omar was evaluated in clinical research aimed at evaluating mucosal recovery in the lining of the esophagus (erosive esophagitis) and ulcers in the stomach or upper intestine. These trials primarily used endoscopy-based assessments, where a doctor directly monitors the internal lining, to measure the mucosal recovery rates after a set duration. For those with endoscopically confirmed ulcers, trials monitored the recovery of the ulcers. Omar was studied for the rates of recurrence of new ulcer formation in high-risk patients.

What remains uncertain is the long-term evidence for the small proportion of patients with the most severe esophagitis who do not achieve complete mucosal recovery after standard initial treatment duration. While extensive research describes recovery patterns, there is limited information for long-term outcomes beyond twelve months for the sustained maintenance of recovery across all subgroups.


Evidence for Helicobacter pylori Eradication Regimens

Omar was evaluated in combination therapy with various antibiotics. The core outcome monitored was the confirmation of H. pylori absence (eradication) by a diagnostic test several weeks after the full treatment course was completed. Research highlights changes measured during the study period related to the measurement of H. pylori presence in combination regimens compared to antibiotic-only regimens. The evidence suggests that tailoring the combination therapy remains a subject of ongoing research. Studies contribute to the broader evidence landscape.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
  2. NIH MedlinePlus on Omeprazole

Frequently Asked Questions (FAQ)

Common questions about Omar (FAQ)


Q: What happens if I miss a dose of Omar?

A: Regulatory documents describe the procedure for a missed dose. If a dose is missed, official information indicates the dose can be taken as soon as it is remembered. However, if it is almost time for the next dose, the official recommendation is to skip the missed dose and resume the regular schedule. Taking two doses at the same time is not advised.

Q: Can I stop taking Omar as soon as I feel better?

A: The medicine is prescribed for a specific duration of use tailored to the medical condition being addressed. Stopping treatment prematurely has been associated with the return of symptoms. The official recommendation is to complete the full prescribed duration as defined by the prescriber.

Q: Is it common for Omar to cause stomach upset?

A: Yes, common adverse reactions listed in official regulatory documents include a range of gastrointestinal effects. These effects, often described as stomach upset, commonly include abdominal pain, nausea, diarrhea, vomiting, and flatulence. These are classified as Common, meaning they are reported in at least 1 in 100 people treated.

Q: Does Omar interact with alcohol?

A: The official label does not document a direct chemical interaction between the medicine and alcohol. However, official documentation suggests avoidance of alcohol while undergoing treatment. Alcohol intake may increase stomach acid and potentially affect the symptoms the drug is intended to address.

Q: Why does the official document list so many potential side effects for Omar?

A: Official regulatory agencies require that drug documents include a comprehensive safety profile. This profile lists all observed effects, whether they occurred during clinical trials or were reported through post-marketing surveillance. These effects are then categorized by how often they occur (Common, Uncommon, Rare) to provide a complete picture of the medicine’s known safety data.

Q: Is Omar a type of antibiotic or something else?

A: Omar, which contains the active ingredient Omeprazole, is not an antibiotic. It is officially classified as a Proton Pump Inhibitor (PPI). Its general purpose is described as the significant and sustained reduction of gastric acid secretion in the stomach.

Q: Does Omar cause weight gain or weight loss?

A: Official regulatory documents, including comprehensive safety profiles and adverse reaction lists, do not list changes in body weight (weight gain or weight loss) as a Common, Uncommon, or Rare adverse reaction.

Q: What are the most serious side effects I should watch out for while on Omar?

A: The official safety profile documents rare but serious adverse reactions that require immediate medical attention. These include severe allergic skin reactions like Severe Cutaneous Adverse Reactions (SCARs) and Acute Interstitial Nephritis (TIN), a serious kidney condition. Regulatory labeling indicates that if signs of a severe reaction occur, immediate medical attention is necessary.

Q: Is it safe to drink coffee or caffeine while taking Omar?

A: Official product information does not document a specific interaction with coffee or caffeine. However, the medicine is advised to be taken before eating to ensure proper action. Certain highly caffeinated or acidic beverages may potentially affect acid production, which could influence the symptoms the medicine is intended to address.

Q: Can children or teenagers use Omar?

A: Regulatory documentation indicates that Omar is approved for certain uses in pediatric patients who are 2 years of age and older. Dosing for children is determined based on their body weight. Official documentation notes that safety and effectiveness are not established for the approved indications in patients under 2 years of age.

Q: Is Omar addictive or habit-forming?

A: The medicine is not classified as a controlled substance by official government authorities, such as the US Drug Enforcement Administration. This status means there is no documented potential for abuse or dependency that requires special regulatory scheduling.

Q: How long can a person usually stay on Omar treatment?

A: The duration of treatment depends entirely on the condition being treated. While acute courses are often 4 to 8 weeks, over-the-counter use is limited to 14 days and should not be repeated within four months unless directed by a doctor. Long-term use is associated with certain safety risks and requires monitoring.

Q: If I have allergies, is it still possible to take Omar?

A: The medicine is not for use in individuals with known allergies or hypersensitivity to the active ingredient, any other ingredients in the product, or to related substituted benzimidazole medicines. Hypersensitivity reactions are listed as possible adverse effects.

Q: How long has Omar been available for prescription use?

A: The active ingredient in Omar, Omeprazole, has been available for prescription use for an extended period. Its initial approval by the U.S. Food and Drug Administration (FDA) for the brand-name version occurred in 1989.

Q: Does Omar affect mood or mental health?

A: Official documentation lists several rare or uncommon adverse reactions that involve the nervous system and mental health. These documented effects include dizziness, insomnia, confusion, and depression.

Q: Is it possible to be allergic to Omar?

A: Yes, official labeling notes that allergic-type reactions are possible. These range from general hypersensitivity reactions to rare but severe reactions like Stevens-Johnson syndrome. Patients with known allergies to similar drugs should review the labeling carefully.

Q: How is Omar typically eliminated from the body?

A: The medicine is extensively metabolized (broken down) in the liver by specific enzymes, as described in the pharmacokinetics section of the label. The majority of the resulting inactive byproducts are then excreted from the body primarily in the urine, with the remainder excreted in the feces.

Q: Is there a maximum time someone is advised to take Omar?

A: Official labeling defines maximum duration for treatment courses. For over-the-counter use, the duration is limited to a 14-day course, not to be repeated for at least four months unless directed by a doctor. Prescription use also has defined short-term limits for most acute conditions.

Q: Will Omar cure my condition, or just manage the symptoms?

A: The therapeutic purpose of Omar is defined by its ability to significantly limit the production of stomach acid. It is approved for the short-term treatment of active conditions and for the long-term maintenance of healing or management of chronic hypersecretory states. Its role is described by its mechanism as an acid-blocking agent.

Q: What is the half-life of Omar?

A: The half-life of a drug refers to the time it takes for its concentration in the bloodstream to be reduced by half. Pharmacokinetic studies documented in official labels state that the plasma half-life of the medicine is very short, typically ranging from 0.5 to 1 hour.

Q: Is a follow-up appointment necessary after starting Omar?

A: Official professional and regulatory guidelines call for periodic reassessment of individuals using the medicine, particularly those on long-term therapy. This is done to help ensure the continued need for treatment and the use of the lowest effective dosage.

Q: Why is the research on Omar sometimes described as 'limited'?

A: The research documentation itself describes the evidence as 'limited' in specific contexts. This includes limitations regarding long-term outcomes beyond twelve months for sustained healing maintenance, and evidence focusing solely on acute, temporary flares of symptoms outside of a continuous treatment plan.

Q: Does Omar come in different strengths or forms (tablet, liquid)?

A: Yes, the medicine is available in multiple forms, as listed in official product information. These include the oral delayed-release capsule and the enteric-coated tablet. It is also available as a powder for Intravenous (IV) injection. Typical oral strengths include 20 mg and 40 mg.

Q: Is it possible to overdose on Omar?

A: Yes, regulatory labeling includes an Overdosage section. Experience with overdosage is documented, with reported symptoms often being transient. The general guidance for overdosage is the use of symptomatic and supportive treatment.

Q: How long does it take for Omar to leave my system completely?

A: The medicine is rapidly eliminated from the bloodstream. Although the drug’s beneficial acid-blocking effect lasts for a sustained period, the medicine itself is almost entirely cleared from the plasma within 3 to 4 hours.

Q: Are there special warnings about Omar for people with heart issues?

A: Regulatory reviews have indicated that long-term use is not likely to be associated with an increased risk of heart problems. However, official safety documentation notes a rare effect of severe low magnesium levels (hypomagnesemia). This specific, rare condition has been associated with the potential for heart rhythm disturbances, according to official safety documentation.

Q: Can men and women use Omar with the same results?

A: Pharmacokinetic studies—which look at how the body processes the drug—have shown some differences in the absorption and elimination of the medicine between men and women. These differences are described in the clinical pharmacology section of the labeling.

Q: Is Omar commonly used for conditions other than its main approval?

A: Regulatory documents explicitly define the conditions for which the medicine has been approved for use, such as the treatment of GERD, Erosive Esophagitis, and active ulcers. The approved uses are restricted to those defined in the official labeling, which ensures the information provided is based on validated research.

How should Omar be stored and disposed of?

How to Store and Dispose of Omar

The official storage and disposal guidelines for Omar (omacetaxine mepesuccinate) are defined by its cytotoxic nature, ensuring stability and safe handling.

Storage Component Official Requirement
Unopened Vial Storage Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), protected from light.
Reconstituted Solution Use within 12 hours if stored at room temperature, or within 6 days if refrigerated (2 C to 8 C).
Handling This is a cytotoxic agent; use special handling (e.g., protective eyewear and gloves) to avoid skin or eye contact during preparation.
Disposal All unused solution and used materials (syringes, needles) must be placed into an appropriate biohazard container. Do not discard in household trash. Patients should return the biohazard container to a clinic or pharmacy for final, appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omar found in:

A-Z Index: